[go: up one dir, main page]

DE69731620D1 - Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten - Google Patents

Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten

Info

Publication number
DE69731620D1
DE69731620D1 DE69731620T DE69731620T DE69731620D1 DE 69731620 D1 DE69731620 D1 DE 69731620D1 DE 69731620 T DE69731620 T DE 69731620T DE 69731620 T DE69731620 T DE 69731620T DE 69731620 D1 DE69731620 D1 DE 69731620D1
Authority
DE
Germany
Prior art keywords
diazepan
benzamides
benzimidazol
aryl
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69731620T
Other languages
English (en)
Inventor
George Daniel Maynard
Michael Kane
Elizabeth Mary Kudlacz
Robin Dalton
Braulio Santiago
D Bratton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69731620D1 publication Critical patent/DE69731620D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69731620T 1996-02-21 1997-01-29 Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten Expired - Lifetime DE69731620D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60459096A 1996-02-21 1996-02-21
US78199797A 1997-01-06 1997-01-06
PCT/US1997/001601 WO1997030991A1 (en) 1996-02-21 1997-01-29 Novel substituted n-methyl-n-(4-(4-(1h-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases

Publications (1)

Publication Number Publication Date
DE69731620D1 true DE69731620D1 (de) 2004-12-23

Family

ID=27084698

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69731620T Expired - Lifetime DE69731620D1 (de) 1996-02-21 1997-01-29 Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten

Country Status (16)

Country Link
EP (1) EP0888338B1 (de)
JP (1) JP2000505083A (de)
KR (1) KR19990087130A (de)
CN (1) CN1143856C (de)
AR (1) AR005897A1 (de)
AT (1) ATE282609T1 (de)
AU (1) AU708738B2 (de)
BR (1) BR9710712A (de)
CA (1) CA2246994C (de)
DE (1) DE69731620D1 (de)
HU (1) HUP9900401A3 (de)
IL (1) IL125605A0 (de)
NO (1) NO983829L (de)
NZ (1) NZ330909A (de)
TW (1) TW440565B (de)
WO (1) WO1997030991A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US7030150B2 (en) * 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
CN112778279B (zh) * 2021-01-25 2021-09-28 苏州正永生物医药有限公司 一种依美斯汀化合物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5879983A (ja) * 1981-11-06 1983-05-13 Kanebo Ltd 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
ATE177095T1 (de) * 1994-08-25 1999-03-15 Merrell Pharma Inc Substituierte piperidine für die behandlung von allergischen krankheiten
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists

Also Published As

Publication number Publication date
AU2253197A (en) 1997-09-10
NO983829L (no) 1998-10-20
CA2246994A1 (en) 1997-08-28
ATE282609T1 (de) 2004-12-15
CN1211248A (zh) 1999-03-17
CA2246994C (en) 2002-04-30
EP0888338B1 (de) 2004-11-17
JP2000505083A (ja) 2000-04-25
KR19990087130A (ko) 1999-12-15
TW440565B (en) 2001-06-16
WO1997030991A1 (en) 1997-08-28
EP0888338A1 (de) 1999-01-07
HUP9900401A3 (en) 2002-10-28
NO983829D0 (no) 1998-08-20
BR9710712A (pt) 1999-08-17
IL125605A0 (en) 1999-03-12
NZ330909A (en) 2001-04-27
AR005897A1 (es) 1999-07-21
AU708738B2 (en) 1999-08-12
CN1143856C (zh) 2004-03-31
HUP9900401A2 (hu) 2000-03-28

Similar Documents

Publication Publication Date Title
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
ATE246500T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE69711034D1 (de) Wässrige fluorpolymerlösungen zur behandlung von harten oberflächen
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATE297917T1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
BR9612074A (pt) Novos 4-(1h-benzimidazol-2-il)(1,4) diazepanos substituidos úteis para o tratamento de doenças alérgicas
DE69731620D1 (de) Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
HUP9901751A3 (en) Novel substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
ATE330938T1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen
DE69714579D1 (de) Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl-amino)-piperidin-1-yl)-2(aryl)butyl)benzamide zur behandlung von allergischen krankheiten
ATE300531T1 (de) Isonipecotamide zur behandlung von integrin vermittelten störungen
ATE226440T1 (de) Zusammensetzung zur behandlung von psoriasis
DE50003481D1 (de) Verwendung von schmutzablösenden formulierungen zur behandlung von oberflächen
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE69813354D1 (de) Mittel zur Behandlung von Herzkrankheiten

Legal Events

Date Code Title Description
8332 No legal effect for de